It is our understanding that the FDA has decided to allow the restoration of his status as a
researcher and the resumption of Investigational New Drug clinical trials overseen by an
Institutional Review Board (IRB) that is beholden to him. Given the behavior of Dr.
Burzynski and the Burzynski Research Institute (BRI) over the course of more than three
decades of failed research and trials, and in the face of a complete lack of scientific
evidence demonstrating the efficacy of their expensive and dangerous antineoplaston
treatment, we find the FDA’s decision perplexing and profoundly disturbing.

40 years of nothing, a bias review board and a whole lot of money funneling to the clinic. FDA says, sure, go ahead.

This is truly a disappointing decision as it appears the FDA failed in their role for consumer protection. I guess the actually knowledgeable people have to step in and smack them across the head. Damn politics inferring…